BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE

biomakrs liquid biopsy scientific paper to be featured on cover on cancers upcoming issue

Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers.

Rashid Ahmed, President and CEO, says, “This latest paper that was published a few days ago paper has been selected by the editors of the journal as the cover of the forthcoming issue. The issue cover will be displayed on the issue page: https://www.mdpi.com/2072-6694/11, and promoted in the issue released notification which will be sent to the journal subscribers together with the table of contents. I would like to thank and acknowledge the team for their excellent contribution that resulted in recognition of this manuscript.”

 The paper is available through : https://www.mdpi.com/2072-6694/11/8/1069 and or at https://www.ncbi.nlm.nih.gov/pubmed/31362354

Cancer Chart

About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).

Read more: https://www.equities.com/news/biomark-s-liquid-biopsy-scientific-paper-to-be-featured-as-cover-on-cancer-s-upcoming-issue-1

Share this post:
Share on facebook
Share on twitter
Share on linkedin
Share on email
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.